Pharmafile Logo
Pharmafocus logo
Advanced Search

multiple sclerosis

Showing 15 posts of 105 posts found.

Novartis’ Gilenya scores paediatric EU approval for advanced relapsing-remitting MS

November 29, 2018
Sales and Marketing Europe, Novartis, UK, multiple sclerosis, pharma

Novartis has announced that Gilenya (fingolimod) has received marketing authorisation from the European Commission for the treatment of relapsing-remitting forms …

News
roche__tree

Roche’s Ocrevus shows earlier, better outcomes in primary progressive and relapsing MS

October 11, 2018
Research and Development Ocrevus, Roche, multiple sclerosis, pharma

Roche has unveiled new five-year data from three Phase 3 open-label extension studies investigating the efficacy of Ocrevus (ocrelizumab) in …

News

NICE rejects Roche’s Ocrevus in primary progressive multiple sclerosis

September 10, 2018
Sales and Marketing NICE, Ocrevus, Roche, UK, multiple sclerosis, pharma

Of the 100,000 MS patients in England, around one in eight have the primary progressive form (PPMS), which brings debilitating …

News
rep

US Congressman arrested over insider trading in biopharma firm

August 9, 2018
Research and Development, Sales and Marketing Chris Collins, Innate, Innate Immunotherapeutics, US, congress, multiple sclerosis, pharma

A Republican Congressman has been arrested by the FBI over on charges of insider trading with shares in Australian biopharmaceutical …

News

Insider Interview: Biosimilars to balance the books

July 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mylan, bisoimilars, multiple sclerosis

Jean-Yves Brault, Country Manager at Mylan UK, discusses how biosimilars are going to play an important role in driving down …

Feature
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

June 29, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Remicade, Roche, biosimilar Amgen, lung cancer, multiple sclerosis, pharma

Summer seems to be in full swing as we reach the end of June, so it’s time to look back …

News
roche__tree

Roche’s Ocrevus cleared for NHS use in relapsing-remitting MS

June 22, 2018
Medical Communications, Sales and Marketing MS, NICE, UK, multiple sclerosis, pharma

Roche and multiple sclerosis (MS) patients across England and Wales are celebrating the news that healthcare watchdog NICE has recommended …

News
roche

Roche’s Ocrevus extends time-to-wheelchair by 7 years in progressive MS patients

June 14, 2018
Research and Development Ocrevus, Roche, multiple sclerosis, pharma

Roche has lifted the curtain on more promising data at Phase 3 for its humanised anti-CD20 monoclonal antibody Ocrevus (ocrelizumab), …

News
european_commission_web

EMA review confirms risks of Abbvie and Biogen’s Zinbryta outweigh benefits

May 21, 2018
Research and Development, Sales and Marketing EMA, Europe, European Commission, PRAC, multiple sclerosis, pharma, zinbryta

The EMA has judged that the benefits offered by Zinbryta (daclizumab), Abbvie and Biogen’s humanised IgG1 monoclonal antibody for the …

News
novartis_side_building

FDA awards first paediatric MS approval to Novartis’ Gilenya

May 14, 2018
Sales and Marketing FDA, gilenya, multiple sclerosis, pharma

The FDA has awarded approval for what it says is its first drug for the treatment of multiple sclerosis (MS) …

News
roche_close

Roche suffers Ocrevus knockback by NICE

April 6, 2018
Medical Communications, Sales and Marketing Ocrevus, Roche, biotech, drugs, multiple sclerosis, pharma, pharmaceutical

Roche’s multiple sclerosis drug, Ocrevus (ocrelizumab), has been a big new growth driver for the company, especially in the US, …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

March 23, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Canada, Celgene, Lundbeck, Marijuana, Novartis, Roche, Vertex, brexit, cannabis, multiple sclerosis, neuroscience, pharma

As me move startlingly quickly towards Easter, it’s time for another Top Ten rundown. This week, Celgene surprised the industry …

News
stem-cell-163711_640

“Game-changer” stem cell transplant shows strength in multiple sclerosis

March 19, 2018
Research and Development, Sales and Marketing Stem cells, multiple sclerosis, pharma

A new stem cell transplant is being hailed as a “game-changer” in the treatment of multiple sclerosis (MS) after an …

News
celgene_1_02

FDA refuses to review Celgene’s ozanimod in multiple sclerosis

February 28, 2018
Research and Development, Sales and Marketing Celgene, FDA, multiple sclerosis, ozanimod, pharma

Celgene has been dealt a heavy blow, revealing that the FDA has rejected its New Drug Application for its sphingosine …

News
biogen_idec_hillerod_2008

Biogen halts Tysabri trial after failure in acute ischemic stroke

February 8, 2018
Research and Development Biogen, Tysabri, multiple sclerosis, pharma, stroke, trial failure

Biogen has halted its investigation into the efficacy of its humanised monoclonal antibody Tysabri (natalizumab) in the treatment of acute …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024